• Publications
  • Influence
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
OBJECTIVES We sought to determine the effect of baroreflex activation therapy (BAT) on systolic blood pressure (SBP) in patients with resistant hypertension. BACKGROUND The Rheos Pivotal TrialExpand
  • 480
  • 22
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.
The purpose of this consensus statement is to offer primary care providers (including physicians, nurse practitioners, and physician assistants) a practical, evidence-based clinical tool forExpand
  • 445
  • 20
  • PDF
Diabetes and Hypertension in Severe Obesity and Effects of Gastric Bypass-Induced Weight Loss
ObjectiveTo evaluate the preoperative relationships of hypertension and diabetes mellitus in severe obesity and the effects of gastric bypass (GBP)-induced weight loss. Summary Background DataSevereExpand
  • 474
  • 15
Case Report and Review of the Literature: Ureteral Endometriosis
  • T. Gehr, D. Sica
  • Medicine
  • The American journal of the medical sciences
  • 1 November 1987
Endometriosis is a common disorder affecting women of all ages. Although urinary tract involvement is not uncommon, ureteral obstruction is an infrequent complication of endometriosis. A case isExpand
  • 332
  • 14
Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing Model
Background—Autonomic dysfunction, characterized by sympathetic activation and vagal withdrawal, contributes to the progression of heart failure (HF). Although the therapeutic benefits of sympatheticExpand
  • 276
  • 13
  • PDF
Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patient's kidney function in both acute andExpand
  • 276
  • 13
  • PDF
Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement.
Since the first International Society on Hypertension in Blacks consensus statement on the "Management of High Blood Pressure in African American" in 2003, data from additional clinical trials haveExpand
  • 277
  • 7
  • PDF
Clinical Pharmacokinetics of Losartan
Losartan is the first orally available angiotensin-receptor antagonist without agonist properties. Following oral administration, losartan is rapidly absorbed, reaching maximum concentrations 1–2Expand
  • 119
  • 7
Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease
Background: Retention of uremic toxins in patients with chronic kidney disease (CKD) negatively affects multiple organ systems, including the cardiovascular system, resulting in significant morbidityExpand
  • 91
  • 7
Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension
Azilsartan medoxomil is an angiotensin receptor blocker (ARB) being developed for hypertension treatment. To compare this ARB with others in the class, we studied the effects of 2 doses of azilsartanExpand
  • 162
  • 6